Oridis Licenses NIH's Proprietary Tissue Microarray Technology
Complete the form below to unlock access to ALL audio articles.
Oridis Biomed has announced that it has entered into a license agreement with the National Institutes of Health (NIH) for the worldwide commercial use of NIH's proprietary Tissue microarray (TMA) technology.
"We are pleased to have been granted by the NIH a license for this TMA technology," said Georg Casari, PhD, Head of ORIDIS Biomed's TISSOMICS™ business.
"This license agreement further strengthens our TISSOMICS™ business for the life-science industry worldwide, where we offer our clients the ability to validate their research, such as biomarker and target verification programs."
Tissue microarrays are a research tool, within Oridis Biomed's TISSOMICS™ platform, that is designed to permit the study of several hundred tissue samples, using standardized high-throughput analysis by in-house pathologists.
